Member of the Association of American Physicians
William Pao mostly deals with Cancer research, Lung cancer, Gefitinib, Erlotinib and Epidermal growth factor receptor. His Cancer research research incorporates elements of Erlotinib Hydrochloride, Tyrosine kinase, Mutation, Molecular biology and EGFR inhibitors. His research in Lung cancer intersects with topics in Cancer, Adenocarcinoma and Drug resistance.
While the research belongs to areas of Gefitinib, William Pao spends his time largely on the problem of Anaplastic lymphoma kinase, intersecting his research to questions surrounding Entrectinib, Receptor Tyrosine Kinase Gene and ROS1. His studies examine the connections between Erlotinib and genetics, as well as such issues in T790M, with regards to Pharmacology, Rociletinib and ABL. His study explores the link between Epidermal growth factor receptor and topics such as Tyrosine-kinase inhibitor that cross with problems in Kinase activity.
His primary areas of study are Cancer research, Lung cancer, Internal medicine, Gefitinib and Oncology. His study in Cancer research is interdisciplinary in nature, drawing from both T790M, Mutation, KRAS, Tyrosine kinase and EGFR inhibitors. The various areas that William Pao examines in his Lung cancer study include Cancer, Targeted therapy, Adenocarcinoma, Bioinformatics and Immunology.
His Internal medicine research is multidisciplinary, incorporating elements of Endocrinology and Surgery. His work focuses on many connections between Gefitinib and other disciplines, such as Erlotinib, that overlap with his field of interest in Pharmacology and Point mutation. The Egfr mutation research William Pao does as part of his general Oncology study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
William Pao spends much of his time researching Cancer research, Lung cancer, Cancer, Internal medicine and Oncology. His biological study spans a wide range of topics, including T790M, Erlotinib, Afatinib, KRAS and MAPK/ERK pathway. As a part of the same scientific family, William Pao mostly works in the field of T790M, focusing on Gefitinib and, on occasion, Osimertinib.
His Erlotinib study is concerned with Epidermal growth factor receptor in general. His Lung cancer research incorporates elements of Exon, Targeted therapy, Immunology and Adenocarcinoma. His Cancer course of study focuses on Mutation and Mutant, DNA repair and Carcinoma.
His primary scientific interests are in Lung cancer, Cancer, Cancer research, Internal medicine and KRAS. William Pao combines subjects such as Disease and Immunology with his study of Lung cancer. His Cancer research research includes themes of Trametinib and MAPK/ERK pathway.
His study looks at the relationship between Internal medicine and topics such as Oncology, which overlap with Targeted therapy. His KRAS study combines topics from a wide range of disciplines, such as Rociletinib, Erlotinib, Gefitinib and Adenocarcinoma. His Gefitinib study combines topics in areas such as EGFR inhibitors and Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty.
Proceedings of the National Academy of Sciences of the United States of America (2004)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely.
PLOS Medicine (2005)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding;Gad Getz;David A. Wheeler;Elaine R. Mardis.
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet.
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima.
Clinical Cancer Research (2013)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller.
PLOS Medicine (2005)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely.
Proceedings of the National Academy of Sciences of the United States of America (2007)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama.
Journal of Clinical Oncology (2012)
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
Marcin Imielinski;Alice H. Berger;Alice H. Berger;Peter S. Hammerman;Peter S. Hammerman;Bryan Hernandez.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Darren A.E. Cross;Susan E. Ashton;Serban Ghiorghiu;Cath Eberlein.
Cancer Discovery (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: